Clinical trials: Lymphoma, Hodgkins
B-Cell Non-Hodgkin Lymphoma
A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
This is an open-label, first-in-human dose escalation and dose expansion Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HP-002 in patients with relapsed or refractory…
- Trial name
- NCT07658352
- Testing
- HP-002
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Shanghai Helioson Pharmaceutical Co., Ltd.
Lymphoma, T-Cell, Peripheral
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
This is a multicenter, single-arm, open label, study consisting of two cohorts. Cohort 2 explores the combination of copanlisib and pembrolizumab in patients with relapsed or refractory NKTCL, who have received at least 1 prior…
- Trial name
- NCT02535247
- Testing
- MK-3475, Copanlisib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Fox Chase Cancer Center
Lymphoma
Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma
RATIONALE: Chemotherapy uses different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gallium nitrate in treating patients with AIDS-related…
- Trial name
- NCT00002578
- Testing
- cytarabine, gallium nitrate, leucovorin calcium
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Roswell Park Cancer Institute
Lymphoma,Non-Hodgkin, Diffuse Large B Cell Lymphoma
The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas
The purpose of this study is to determine whether the CD16- monocyte/CD16+ monocyte ratio could help predict the prognosis of DLBCL and PTCL.
- Conditions
- Lymphoma,Non-Hodgkin, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
- Trial name
- NCT03000738
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Hodgkin Lymphoma
Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma
Pilot open-label study to estimate the feasibility, safety and efficacy of intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ…
- Trial name
- NCT02624258
- Testing
- CD19 RNA redirected autologous T-cells (RNA CART19 cells)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pennsylvania
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin's Lymphoma
RATIONALE: AT7519M may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of AT7519M in treating patients with advanced…
- Trial name
- NCT00390117
- Testing
- CDKI AT7519, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Hodgkin Lymphoma
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
The purpose of the phase Ib of the study is to identify the maximum tolerated dose (MTD) of Brentuximab Vedotin (BV) in combination with EPEM and to assess the toxicity of the combination of BV with EPEM.
- Trial name
- NCT03576378
- Testing
- BrentuximabVedotin (BV)
- Where
- 15 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Mantle Cell Lymphoma
Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to assess the safety, tolerability and activity of the combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell lymphoma who are not eligible for high dose…
- Trial name
- NCT01170052
- Testing
- Temsirolimus, Bendamustine
- Where
- 3 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Charite University, Berlin, Germany
Graft Versus Host Disease, Leukemia
Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and melphalan, before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myeloma
- Trial name
- ProT4 (NCT01240525)
- Testing
- CD4 DLI, No DLI
- Where
- 11 sites in United Kingdom
- Volunteers
- 114 people
- Sponsor
- University College, London
Lymphoma
Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00005824
- Testing
- filgrastim, busulfan, cyclophosphamide
- Where
- 2 sites in United States
- Sponsor
- AIDS Malignancy Consortium
Non Hodgkin Lymphoma
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
This is an open-label, non-randomized clinical study to evaluate the pharmacokinetic (PK) profiles, safety, tolerability and preliminary efficacy of oral abexinostat monotherapy in patients with non-Hodgkin's lymphoma who have…
- Trial name
- NCT04024696
- Testing
- Abexinostat
- Where
- 4 sites in China
- Volunteers
- 12 people
- Sponsor
- Xynomic Pharmaceuticals, Inc.
Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma
Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma
The purpose of this research study is to determine the highest and safest dose of the experimental drug veliparib when combined with nivolumab.
- Conditions
- Advanced Solid Neoplasm, Aggressive Non-Hodgkin Lymphoma, Recurrent Solid Neoplasm, Refractory Mantle Cell Lymphoma
- Trial name
- NCT03061188
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Chronic Lymphocytic Leukemia, Graft vs Host Disease
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
Cancers of the blood, sometimes referred to as hematologic malignancies, are disorders of bone marrow cells that lead to the failure of the normal function of bone marrow and the uncontrolled growth of cancerous cells in the bone…
- Conditions
- Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hematologic Neoplasm, Multiple Myeloma
- Trial name
- NCT00001873
- Testing
- Isolex 300i plus MoAbs
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloproliferative Disorders, Leukemia
Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003082
- Testing
- monoclonal antibody A27.15, monoclonal antibody E2.3
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Arizona
Anemia, Leukemia
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
RATIONALE: Epoetin alfa and darbepoetin alfa may cause the body to make more red blood cells. They are used to treat anemia caused by chemotherapy in patients with cancer.
- Conditions
- Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00416624
- Testing
- darbepoetin alfa, epoetin alfa, fatigue assessment and management
- Where
- United States
- Volunteers
- 239 people
- Sponsor
- Mayo Clinic
B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT06533579
- Testing
- Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Vironexis Biotherapeutics Inc.
Mantle Cell Lymphoma Recurrent
Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma
This is an open label, multi-center, single-arm, phase II study investigating the efficacy and safety of the combination of ibrutinib and Tisagenlecleucel in twenty patients with relapsed or refractory Mantle Cell Lymphoma (MCL)…
- Trial name
- TARMAC (NCT04234061)
- Testing
- ibrutinib and Tisagenlecleucel
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
This phase I trial studies the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has…
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder
- Trial name
- NCT02153580
- Testing
- Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Bendamustine Hydrochloride, Cyclophosphamide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- City of Hope Medical Center
Hematologic Malignancies
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer
The purpose of this study is to characterize the safety and tolerability of repeat doses of compound GSK2110183 in subjects with hematologic cancer.
- Trial name
- NCT00881946
- Testing
- GSK21110183
- Where
- 4 sites in Australia, Canada and 1 more
- Volunteers
- 73 people
- Sponsor
- Accenture
Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide.
- Trial name
- OLYMPIA-5 (NCT06149286)
- Testing
- Odronextamab, Lenalidomide, Rituximab
- Where
- 171 sites in United States, Australia and 16 more
- Volunteers
- 580 people
- Sponsor
- Regeneron Pharmaceuticals